PRESENTATION

Q1 2023 — Presentation

Q1 2023PDF · 30 pages2.0 MB
Merck
Q1 2023 Earnings
April 27, 2023

-- 1 of 30 --

Agenda
2
Strategy and
Business Update
Rob Davis
Chairman and Chief
Executive Officer
Question & Answer
Session
Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer
Research
Update
Dr. Dean Li
President, Merck
Research Laboratories

-- 2 of 30 --

Forward-looking statement of Merck & Co., Inc.,
Rahway, N.J., USA
3
This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe
harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations
of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates
that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions
prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate
and currency exchange rate fluctuations; the impact of the global outbreak of novel coronavirus disease (COVID-19); the impact of pharmaceutical
industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment;
technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining
regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of
international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products;
and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or
otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the
company’s Annual Report on Form 10-K for the year ended December 31, 2022 and the company’s other filings with the Securities and Exchange
Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

-- 3 of 30 --

Strategy &
Business Update
Rob Davis
Chairman and Chief Executive Officer

-- 4 of 30 --

Delivered on our key strategic priorities in 1Q 2023
5
Advanced the pipeline to meet
patient unmet need
Achieved strong commercial and
financial performance
Executed on strategic business
development to enhance pipeline
Created long-term value for patients
and shareholders

-- 5 of 30 --

6
Merck continues to advance science-led strategy through
acquisition of Prometheus Biosciences
6
Potentially transformational, first-in-class, late-stage candidate,
in a disease area with significant unmet medical need
+
Opportunity to potentially transform standard of care for certain
patients suffering from debilitating autoimmune diseases through
precision medicine approach
Multi-billion dollar commercial opportunity with potential to drive
long-term revenue and earnings growth well into the next decade
Diversifies portfolio and enhances our sustainable innovation engine

-- 6 of 30 --

Very significant 1Q sales and underlying earnings growth1
7
1. Results from continuing operations attributable to Merck & Co., Inc. 2. Merck does not exclude expenses for upfront and milestone payments related to collaborations and licensing agreements, or charges related to pre-
approval assets obtained in transactions accounted for as asset acquisitions from its non-GAAP results. Full year 2022 non-GAAP results include $690 million or $0.22 of such charges. Full year 2021 non-GAAP results include
$1.7 billion or $0.65 of such charges. 1Q23 non-GAAP results include $1.4 billion or $0.52 of such charges. For 2023, outlook does not assume the proposed acquisition of Prometheus or any additional significant potential
business development transactions. 3. GAAP EPS of $1.11. 4. 2023 GAAP guidance range of $5.85 to $5.97.
$41.5B
+6%
$48.7B
+17%
GUIDANCE
RANGE
$57.5B-$58.5B
$14.5B
-9%
+15% ex-Exchange, ex-LAGEVRIO
1Q Worldwide Sales
$1.40
-35%
1Q Non-GAAP EPS2,3
2021 	2022 	2023
$48.7B
+17%
2021 	2022 	2023
$5.37
Full Year Sales
Full Year Non-GAAP EPS2
$59.3B
+22%
$7.48
GUIDANCE
RANGE
$57.7B - $58.9B
GUIDANCE
RANGE
$6.88 - $7.00

-- 7 of 30 --

Advancing and augmenting deep pipeline in 1Q
8
Cardiovascular
Oncology
• 	Presented detailed results from Phase 2b trial evaluating
KEYTRUDA in combination with mRNA-4157/V940, an
investigational individualized neoantigen therapy, with
partner Moderna, for the adjuvant treatment of patients
with stage III/IV melanoma following complete resection
at AACR
• 	Announced positive topline results from Phase 3 KN-671
trial evaluating KEYTRUDA regimen as
neoadjuvant/adjuvant treatment in patients with
resectable stage II, IIIA or IIIB NSCLC
• 	Presented positive Phase 3 data from the STELLAR
trial evaluating sotatercept at ACC.23/WCC
• 	Presented positive Phase 2 data for MK-0616 at
ACC.23/WCC
• 	Hosted investor event to discuss data and provide
overview of broader research efforts in cardiology
Translating breakthrough science into
medicines and vaccines
that save and improve lives
Building a sustainable
innovation engine

-- 8 of 30 --

Business/Financial
Results and Outlook
Caroline Litchfield
Chief Financial Officer

-- 9 of 30 --

Strong underlying Q1 sales growth
across Human Health and Animal Health
10
Merck
WORLDWIDE SALES1,2
$14.5B-9% growth
+11% ex-LAGEVRIO3
+15% ex-exchange, ex-LAGEVRIO4
$12.7B
-10% growth
+14% ex-LAGEVRIO3
+18% ex-exchange, ex-LAGEVRIO4
Human Health
$1.5B
+1% growth
+5% ex-exchange
Animal Health
1. Results attributable to Merck & Co., Inc. 2. Worldwide Sales includes Other Revenue 3. Excludes Lagevrio sales of $392 million in 1Q23 and $3.2 billion in 1Q22.
4. Excludes Lagevrio sales of $392 million in 1Q23 and $3.2 billion in 1Q22 and foreign exchange

-- 10 of 30 --

Oncology: KEYTRUDA drives strong growth
11	Growth rates exclude the impact of foreign exchange.
• KEYTRUDA sales of $5.8B increased 24%
year-over-year, driven by strong global
demand in metastatic cancers
and increased uptake from earlier-stage
indications
– In the U.S., growth of 25% reflects strong
uptake across in earlier-stage cancers such as
TNBC, as well as certain types of renal cell
carcinoma and melanoma
– Ex-U.S., 22% increase driven by continued
global uptake in metastatic RCC as well as
earlier-stage cancers, including high-risk early
stage TNBC
$4.2B
+20%
$3.4B
+31%
$5.3B
+30%
1Q21 	1Q22 	1Q23
$4.8B
+27%
$3.9B
+16%
$5.8B
+24%

-- 11 of 30 --

Oncology: Solid performance across broad portfolio
• Lynparza 1 sales grew 8% driven primarily by
increased demand in key European markets
in certain patients with ovarian cancer
• Lenvima 2 sales grew 5% due to increased
uptake in advanced RCC in key European
markets
$248M
+34%	$178M
+62%
$275M
+17%
$181M
+15%
$151M
+57%
$231M
+33%
12	Increase/decrease in sales exclude the impact of foreign exchange.
1 In collaboration with AstraZeneca; 2 In collaboration with Eisai
1Q21 	1Q22 	1Q23
1Q21 	1Q22 	1Q23
$266M
+20%$228M
+51%
$275M
+8%
$227M
+77%
$130M
-1%
$232M
+5%

-- 12 of 30 --

Vaccines: GARDASIL growth driven by strong international demand
13
• GARDASIL sales of $2.0B increased 43%
year-over-year primarily driven by strong
underlying demand outside the U.S.,
particularly China, as well as increased
supply
– China growth also benefitted from an
acceleration of shipments from 2H to 1H to
ensure availability of product to meet
heightened demand following the approval
of the expanded indication of GARDASIL 9
for girls and women 9 to 45 years of age
• Strong ongoing pediatric launch of
VAXNEUVANCE is tracking with
expectations
$1.2B
+78%
$656M
-24%
$1.7B
+40%
1Q21 	1Q22 	1Q23
$1.5B
+60%
$917M
-20%
$2.0B
+43%
Growth rates exclude the impact of foreign exchange.

-- 13 of 30 --

Hospital: Strong global demand across key products
14
• BRIDION sales of $487M increased 27%
primarily due to greater share among
neuromuscular blockade reversal agents
• PREVYMIS sales grew 44% driven by
continued strong global demand
$387M
+67%
$224M
-18%
$426M
+15%
1Q21 	1Q22 	1Q23
$395M
+20%$340M
+11%
$487M
+27%
$93M
+41%$63M
+67%
$103M
+18%
1Q21 	1Q22 	1Q23
$94M
+20%
$82M
+31%
$129M
+44%
Growth rates exclude the impact of foreign exchange.

-- 14 of 30 --

Animal Health: Solid growth driven by livestock
15
• Animal Health sales increased 5% to $1.5B,
reflecting strong demand across livestock
portfolio, as well as strategic price actions
– Livestock growth of 8% due to strong
performance in ruminants and poultry products
– Companion Animal results reflect increased
sales of Bravecto, partially offset by supply
challenges for certain vaccines
$1.5B
+27%
$1.1B
+3%
$1.5B
+5%
1Q21 	1Q22 	1Q23
$1.5B
+9%	$1.4B
+15%
$1.5B
+5%
Growth rates exclude the impact of foreign exchange.

-- 15 of 30 --

Q1 2023 continuing operations non-GAAP financial results summary 1
Q1 2023 	Q1 2022 	Change Change
Ex-FX
Sales 	$14.5 	$15.9 	-9% 	-5%
Non-GAAP Gross
Margin 76.9% 	70.7% 	+6.1pts 	+5.9pts
Non-GAAP Operating
Expenses 2 $6.7 	$4.8 	+40% 	+42%
Non-GAAP Tax Rate 	20.4% 	14.0% 	+6.4pts 	N/A
Non-GAAP EPS3 $1.40 	$2.14 	-35% 	-30%
$ in billions, except EPS amounts
16
1. Merck is providing certain 2023 and 2022 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business
performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results because management uses non-GAAP results to assess
performance. Management uses non-GAAP measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior
management’s annual compensation is derived in part using a non-GAAP pre-tax income metric. This information should be considered in addition to, but not as a substitute for or superior to,
information prepared in accordance with GAAP. For a description of the non-GAAP adjustments, see Table 2a attached to this release. 2. For Q1 Non-GAAP results include $1.4 billion of R&D
expense, or an estimated $0.52 of negative impact to EPS, related to an asset acquisition, and collaboration and licensing agreement. 3. Q1 2023 GAAP EPS of $1.11.

-- 16 of 30 --

Merck updated full-year 2023 guidance
1. GAAP Gross Margin Rate: ~73% 2. GAAP Operating Expenses: $23.5 to $24.3 billion 3. GAAP Tax Rate: ~17-18% 4. The GAAP to non-GAAP reconciliation is available in Merck’s Q1 2023 earnings
release 5. Merck includes expenses for upfront and milestone payments related to collaborations and licensing agreements, as well as charges related to pre-approval assets obtained in transactions
accounted for as asset acquisitions from its non-GAAP results 6. The proposed Prometheus Biosciences acquisition is anticipated to result in a one-time charge of approximately $10.3 billion recorded
to both GAAP and non-GAAP R&D expenses in 2023 or approximately $4.00 per share, as well as an approximate $0.25 negative impact on EPS in the first 12 months following close. 	17
Prior Guidance 	Updated Guidance 	Key Assumptions
Revenue $57.2B to $58.7B
-4% to -1% (-2% to +1% ex-FX)
$57.7B to $58.9B
-3% to -1% (-1% to +1% ex-FX)
• 	Includes approximately $1B of LAGEVRIO revenue
• 	Ex-LAGEVRIO, growth of 6% to 8% (8 to 10% ex-FX)
• 	Assumes ~2% FX headwind
Non-GAAP
Gross Margin Rate 1 	~77.0% 	~77.0%
Non-GAAP
Operating Expenses2,5,6 	$23.1B to $24.1B 	$23.3B to $24.1B
• 	Includes $1.4B of upfront R&D expense related to
acquisition of Imago Biosciences and expansion of
collaboration with Kelun Biotech
• 	Does not include the proposed acquisition of Prometheus
Biosciences6
Other (Income) / Expense 	~$250M of income 	~$250M of income
Tax Rate 3 	~17.0%-18.0% 	~17.0%-18.0%
Shares Outstanding 	~2.55B 	~2.55B 	• 	Assumes modest share repurchase
GAAP EPS 	$5.86 to $6.01 	$5.85 to $5.97
Non-GAAP EPS4,5,6 	$6.80 to $6.95 	$6.88 to $7.00
• 	Includes $0.52 of charges related to an acquisition, and
significant collaborations and licensing agreement
• 	Assumes ~4% FX headwind

-- 17 of 30 --

Key modeling considerations
KEYTRUDA 	GARDASIL
• 	In the U.S., exceptional growth in prior quarters is expected to
moderate as strong uptake from recently launched indications,
particularly in earlier-stage cancers, is annualized
• 	Ex-U.S., expect strong volume growth to be partially offset by
pricing headwinds, particularly in key European markets
18
• 	Expect strong growth driven by robust global demand,
particularly in ex-U.S. markets
• 	Expect an acceleration of full year growth in 2023 relative to
2022, though not at the same rate of growth as in Q1 2023

-- 18 of 30 --

19
Continue to prioritize
investments in our
pipeline and business
to realize value
of near- and long-term
opportunities
$3.4
$1.0
$1.9 	$1.9
$0.1
After-Tax R&D 	CapEx 	Dividends
Paid
Business
Development
(ex-divestitures)
Share Repurchase
$ Billions1
1. Reflects Q1 spend
Remain committed to balanced capital allocation strategy
Capital allocation order of priority

-- 19 of 30 --

Research Update
Dr. Dean Li
President, Merck Research Laboratories

-- 20 of 30 --

Driving value for patients and shareholders by progressing our pipeline
21
Key regulatory milestones
since the last earnings call:
Key data & clinical advancements
since the last earnings call:
• 	In the U.S., the FDA:
o 	Converted from accelerated to full approval indication for KEYTRUDA in
patients with unresectable or metastatic microsatellite instability-high (MSI-
H) or mismatch repair deficient (dMMR) solid tumors, as determined by an
FDA-approved test, that have progressed following prior treatment and who
have no satisfactory alternative treatment option
o 	Granted accelerated approval of KEYTRUDA in combination with enfortumab
vedotin, for the treatment of adult patients with locally advanced or
metastatic urothelial carcinoma who are not eligible for cisplatin-containing
chemotherapy based on KEYNOTE-869
o 	Accepted sBLA for KEYTRUDA in combination with chemotherapy for the
treatment of HER2-negative locally advanced unresectable or metastatic
gastric or GEJ adenocarcinoma regardless of PD-L1 expression based on
KEYNOTE-859
o 	Granted Breakthrough Therapy Designation for mRNA-4157/V940 in
combination with KEYTRUDA the adjuvant treatment of high-risk melanoma
following complete resection
o 	Approved expanded administration option for intramuscular route of
administration for the MMRV family of vaccines, M-M-RII, VARIVAX and
ProQuad
o 	Accepted priority review for the sNDA for PREVYMIS for prophylaxis of
cytomegalovirus (CMV) disease in adult kidney transplant recipients at high
risk
• 	In Europe, the EMA:
o 	Granted Priority Medicines scheme designation for mRNA-4157/V940 in
combination with KEYTRUDA for the treatment of high-risk adjuvant
melanoma following complete resection
• 	In Japan, the MHLW:
o 	Approved LAGEVRIO for the treatment of COVID-19
1. In collaboration with AstraZeneca 2. In collaboration with Moderna 3. In collaboration with Gilead
• 	Presented results of the Phase 3 STELLAR trial evaluating sotatercept, a novel
investigational activin signaling inhibitor biologic, in combination with stable
background therapy for the treatment of adult patients with pulmonary arterial
hypertension and the Phase 2b clinical trial evaluating MK-0616, an investigational
oral PCSK9 candidate, for adult patients with hypercholesterolemia at ACC.23/WCC
• 	Presented final results of key secondary overall survival endpoint from Phase 3
PROpel trial evaluating Lynparza1 in combination with abiraterone and prednisone or
prednisolone at 2023 ASCO Genitourinary Cancers Symposium
• 	Announced Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA in combination with
chemotherapy as a perioperative treatment regimen for patients with resectable
stage II, IIIA or IIIB non-small cell lung cancer met one of its dual primary endpoints of
event-free survival
• 	Announced results of Phase 3 NRG-GY018 trial evaluating KEYTRUDA in
combination with chemotherapy then continued as a single agent for the treatment
of patients with stage III-IV or recurrent endometrial carcinoma whose cancer was
either mismatch repair proficient or mismatch repair deficient
• 	Announced results of Phase 2/3 KEYNOTE-483 trial evaluating KEYTRUDA in
combination with chemotherapy as first-line treatment for patients with
unresectable advanced or metastatic malignant pleural mesothelioma met its
primary endpoint of overall survival
• 	Announced results of Phase 2 KEYNOTE-942 trial evaluating KEYTRUDA in
combination with mRNA-4157/V9402 for the treatment of high-risk adjuvant
melanoma following complete resection at AACR
• 	Opened enrollment for new Phase 3 clinical trials with investigational once-daily
islatravir in combination with doravirine and Phase 2 clinical trial with once-weekly
islatravir in combination with lenacapavir3 for treatment of HIV-1 infection

-- 21 of 30 --

Making tangible advancements in our cardiovascular pipeline
Sotatercept 	MK-0616
• 	Presented Phase 3 results from the STELLAR trial
• 	Substantial improvement of 40.8 meters in 6MWD at
Week 24
• 	Met 8 out of 9 secondary endpoints including:
o 	84% reduction in risk of death or clinical
worsening events1
• 	Advancing broad program, including Phase 3 HYPERION,
ZENITH, SOTERIA and Phase 2 CADENCE studies
• 	Presented Phase 2b results
• 	Reduction of LDL-cholesterol levels from 41.2 up to 60.9 %
vs placebo, across 4 doses in study
• 	Eighty to 90% of patients receiving MK-0616 were able to
reach their LDL-C goals
• 	Defined path toward providing a therapy that could achieve
broad global access
• 	Initiating multiple Phase 3 studies including a cardiovascular
outcomes trial
22
1. TTCW is time to clinical worsening or death (defined by death of any cause or specified non-fatal clinical worsening events); sotatercept plus stable background therapy reduced the risk of clinical worsening or death by 84%
compared to placebo plus background therapy with a median follow-up of 32.7 weeks (HR=0.16 [95% CI, 0.08-0.35]; p<0.001

-- 22 of 30 --

23
Developing treatments for earlier stages of cancer
remains a key area of focus and execution
At AACR, in collaboration with Moderna, announced
detailed results from Phase 2b KEYNOTE-942
investigating the combination of KEYTRUDA and
MRNA-4157/V490, an individualized neoantigen
therapy
The 18-month RFS rate was 78.6% (95% CI, 69.0-85.6) and
62.2% (95% CI, 46.9-74.3) in the combination and control arms,
respectively
Making progress in the treatment of earlier stage
NSCLC through multiple clinical trials
APPROVED
KEYNOTE-091: Received FDA approval for KEYTRUDA
for adjuvant treatment of adult patients with stage IB
(T2a >=4 cm), II or IIIA NSCLC following resection and
platinum-based chemotherapy
PHASE III
 
KEYNOTE-867: Evaluating KEYTRUDA in patients
undergoing stereotactic body radiotherapy with
unresected stage I or II NSCLC
KEYLYNK-012: Evaluating KEYTRUDA in combination
with Lynparza1 in stage III disease
1. In collaboration with AstraZeneca
FILED
 	KEYNOTE-671: Announced positive top line results for
KEYTRUDA with platinum doublet chemotherapy as
neoadjuvant followed by adjuvant therapy for patients
with resectable stage II, IIIA and IIIB NSCLC
KEYTRUDA
Immunotherapy that
increases the ability of
the body’s immune
system to help detect
and fight tumor cells
mRNA-4157/V940
Designed to stimulate
an immune response
by generating specific
T cell responses based on
the unique mutational
signature of a
patient’s tumor

-- 23 of 30 --

24
Advancing our broader oncology portfolio
Adenocarcinoma 	Prostate	Women’s Cancers	Antibody Drug Conjugates
1. In collaboration with Orion
• NRG-GY018: Announced positive
data for KEYTRUDA in
combination with chemotherapy
for 1L treatment of patients with
stage III to IV of recurrent
endometrial carcinoma
• Building upon approvals based on
KEYNOTE-146, KEYNOTE-775
and KEYNOTE-158 in endometrial
cancer
• KEYNOTE-859: FDA accepted
application for KEYTRUDA in
combination with chemotherapy
in HER2- negative locally
advanced unresectable or
metastatic gastric or
gastroesophageal junction
adenocarcinoma
• Remain committed to
addressing this area of
significant unmet patient need
• Planning to initiate Phase 3
trials for MK-5684 1, a novel
oral non-steroidal inhibitor
of CYP-11A1, by the end of
2023
• KEYNOTE-869: Announced
accelerated approval of
KEYTRUDA, in combination
with enfortumab vedotin, an
anti-body drug conjugate, for
the treatment of adult patients
with locally advanced or
metastatic urothelial
carcinoma who are not eligible
for cisplatin-containing
chemotherapy
• Kelun-Biotech: Planning to
initiate multiple Phase 3 trials
for MK-2870, a TROP-2
targeting ADC, as
monotherapy and in
combination with KEYTRUDA

-- 24 of 30 --

25
Expanding our broader pipeline and portfolio
Infectious Disease 	Immunology
+
• HIV
– 	Enrolling multiple new Phase 3 studies for once-daily
islatravir in combination with doravirine
– 	Resumed the Phase 2 study of an oral once-weekly
combination treatment regimen of islatravir and Gilead’s
lenacapavir
• COVID-19
– 	Received full approval for LAGEVRIO for the treatment of
COVID-19 by the Ministry of Health Labor and Welfare in
Japan
• 	Proposed acquisition of Prometheus Biosciences augments
and accelerates ongoing research efforts in immunology
• 	PRA023 is a potential first-in-class late-stage clinical
candidate with positive Phase 2 results in ulcerative colitis and
Crohn’s Disease
• 	Suite of immunology pipeline compounds including PRA052
• 	Deep genetic and biological insights from Prometheus 360
Data Science Platform

-- 25 of 30 --

Q&A
Rob Davis
Chairman & Chief Executive Officer
Caroline Litchfield
Chief Financial Officer
Dr. Dean Li
President, Merck Research Laboratories
Peter Dannenbaum
Vice President, Investor Relations

-- 26 of 30 --

Appendix
27

-- 27 of 30 --

Q1 2023 GAAP financial results summary
28
Q1 2023 	Q1 2022 	Change Change
Ex-FX
Sales 	$14.5 	$15.9 	-9% 	-5%
Operating Expenses 	$6.8 	$4.9 	+38% 	+40%
Tax Rate 	22.6% 	11.4% 	+11.2pts 	N/A
GAAP EPS 	$1.11 	$1.70 	-35% 	-30%
$ in billions, except EPS amounts

-- 28 of 30 --

$11.4
$4.4
$7.1
$3.5 $0.1
$0
$3
$6
$9
$12
After-Tax R&D 	CapEx 	Dividends Paid 	Business
Development
(ex-divestitures)
Share
Repurchase
Capital allocation: Trailing twelve months
~$18B
Over 5 years, including expanding
manufacturing capacity for Oncology, Vaccines,
and Animal Health. Includes >$10B in the U.S.
Billions
$1.76 	$1.80 	$1.84 	$1.88 	$1.92
$2.20
$2.44
$2.60
$2.76
$2.92
$1.40
$1.70
$2.00
$2.30
$2.60
$2.90
$3.20
2014 	2015 	2016 	2017 	2018 	2019 	2020 	2021 	2022 	2023
Dollars per share	
+2% 	+2% 	+2% +2% 	+2%
+11%
+15%
+7%
Over the past 12 months
Capital investments
2022 to 2026
Commitment to the dividend
29
Well positioned balance sheet
with capacity to fund
additional value-enhancing
business development
opportunities
+6%
Order of priority
+6%
E
1. Includes payments reflected in operating cash flow
1

-- 29 of 30 --

Phase 2 	Phase 3 	Under regulatory review
Oncology
V181
Dengue Fever Virus
Vaccines
Infectious diseases
MK-8189 4
Schizophrenia
Neuroscience
Gefapixant (MK-7264)
Cough (US, EU)
General medicine
General medicine
As of April 27, 2023
V114
Pneumococcal Vaccine, pediatric (JPN)
Vaccines
Infectious diseases
Oncology 	Oncology
MK-1942
Treatment Resistant Depression
MK-6024 (efinopegdutide)
NASH
MK-8591B (islatravir+MK-8507) 1
HIV-1 Infection
MK-8591D (islatravir+lenacapavir) 2
HIV-1 Infection
KEYTRUDA (MK-3475)
Biliary
CSCC (EU)
Hepatocellular (EU)
Mesothelioma
Ovarian
SCLC
MK-1026 (nemtabrutinib)
Hematological Malignancies
MK-1308A (quavonlimab
+pembrolizumab)
RCC
MK-7684A (vibostolimab
+pembrolizumab)
Melanoma
NSCLC
SCLC
MK-4280A (favezelimab
+pembrolizumab)
CRC
Hematological Malignancies
LENVIMA (MK-7902)
Esophageal
Gastric
HNSCC
NSCLC
LYNPARZA (MK-7339)
NSCLC
SCLC
WELIREG (MK-6482)
RCC
TUKYSA (MK-7119)
Breast
CRC
MK-3475
(pembrolizumab
subcutaneous)
NSCLC
MK-3475A
(pembrolizumab
+hyaluronidase)
NSCLC
MK-8591A (doravirine+islatravir) 2
HIV-1 Infection
LAGEVRIO (MK-4482) 3
COVID-19 antiviral
KEYTRUDA (MK-3475)
2L HCC (US)
LA Merkel Cell (US)
Adjuvant NSCLC (EU)
1L HER2- Gastric (US, EU)
Resectable NSCLC (US, EU)
B-Cell Lymphoma (JPN)
LYNPARZA (MK-7339)
Metastatic 1L Prostate (US, JPN)
MK-0616
Hypercholesterolemia
MK-2060
Thrombosis
MK-5475
Pulmonary Arterial Hypertension
MK-7962 (sotatercept)
Pulmonary Hypertension due to Left
Heart Disease
Cardiovascular
MK-4830
CRC
Esophageal
Melanoma
NSCLC
Ovarian
RCC
SCLC
MK-5684
Prostate
MK-5890 (boserolimab)
NSCLC
SCLC
MK-6440
(ladiratuzumab vedotin)
Breast
Esophageal
Gastric
HNSCC
Melanoma
NSCLC
Prostate
SCLC
MK-2870
Neoplasm Malignant
KEYTRUDA (MK-3475)
Advanced Solid Tumors
Prostate
MK-3543
(bomedemstat)
Myeloproliferative
Disorders
MK-4280
(favezelimab)
NSCLC
MK-4280A
(favezelimab+pembroli
zumab)
Bladder
Esophageal
Melanoma
RCC
SCLC
WELIREG (MK-6482)
Biliary
Certain VHL tumors (EU)
CRC
Endometrial
Esophageal
HCC
Pancreatic
Rare Cancers
LYNPARZA (MK-7339)
Advanced Solid Tumors
LENVIMA (MK-7902)
Biliary
Melanoma
Pancreas
Prostate
SCLC
mRNA-4157/V940
Melanoma
MK-7684A
(vibostolimab
+pembrolizumab)
Biliary
Bladder
Breast
Cervical
CRC
Endometrial
Esophageal
Gastric
HCC
HNSCC
Hematological Malignancies
Ovarian
Prostate
TUKYSA (MK-7119)
Advanced Solid Tumors
Bladder
Biliary
Cervical
Endometrial
Gastric
NSCLC
MK-0482
NSCLC
MK-1308 (quavonlimab)
NSCLC
MK-1308A
(quavonlimab
+pembrolizumab)
CRC
HCC
Melanoma
SCLC
MK-2140 (zilovertamab
vedotin)
Bladder
Breast
Gastric
Hematological Malignancies
NSCLC
Ovarian
Pancreas
Broad and innovative pipeline to solve significant unmet medical needs
30
Vaccines
MK-1654 (clesrovimab)
Respiratory Syncytial
Virus (RSV)
1 On FDA clinical hold 2On FDA partial clinical hold for higher doses than those used in current clinical trials	
3 Available in the US under EUA 4 Development is co-funded by Royalty Pharma	
5 Requested re-examination of EU MAA following CHMP major objection of data to support market authorization
MK-7962 (sotatercept)
Pulmonary Arterial Hypertension
Cardiovascular
Infectious diseases
LAGEVRIO (MK-4482) 5
COVID-19 antiviral (EU)
V116
Pneumococcal vaccine,
adult
Hospital
PREVYMIS (MK-8228)
Prophylaxis of CMW in kidney transplant patients

-- 30 of 30 --